Identification

Name
Bromocriptine
Accession Number
DB01200  (APRD00622)
Type
Small Molecule
Groups
Approved, Investigational
Description

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.

Structure
Thumb
Synonyms
  • (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
  • (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
  • (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
  • 2-Bromo-alpha-ergocryptine
  • 2-Bromo-alpha-ergokryptin
  • 2-Bromo-alpha-ergokryptine
  • 2-bromo-α-ergocryptine
  • 2-bromo-α-ergokryptin
  • 2-bromo-α-ergokryptine
  • Bromocriptina
  • Bromocriptinum
  • Bromocryptine
  • Bromoergocriptine
  • Bromoergocryptine
External IDs
SANDOZ 15-754
Product Ingredients
IngredientUNIICASInChI Key
Bromocriptine mesylateFFP983J3OD22260-51-1NOJMTMIRQRDZMT-GSPXQYRGSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromocriptineCapsule5 mgOralPharmel Inc1998-09-03Not applicableCanada
BromocriptineCapsule5 mgOralAa Pharma Inc1997-01-08Not applicableCanada
BromocriptineTablet2.5 mgOralPharmel Inc1998-09-03Not applicableCanada
BromocriptineTablet2.5 mgOralAa Pharma Inc1994-12-31Not applicableCanada
Bromocriptine MesylateCapsule5 mg/1OralRanbaxy Inc.2016-12-22Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralRanbaxy Inc.2016-12-22Not applicableUs
Bromocriptine-2.5 - Tab 2.5mgTablet2.5 mgOralPro Doc Limitee1996-12-312010-07-13Canada
Bromocriptine-5Capsule5 mgOralPro Doc Limitee1998-08-112010-07-13Canada
Co Bromocriptine Capsules 5mgCapsule5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Co Bromocriptine Tablets 2.5mgTablet2.5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bromocriptine mesylateTablet2.5 mg/1OralKaiser Foundations Hospitals2017-02-14Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralKaiser Foundations Hospitals2014-10-10Not applicableUs
Bromocriptine mesylateCapsule5 mg/1OralZydus Pharmaceuticals Usa, Inc.2009-01-23Not applicableUs
Bromocriptine mesylateTablet2.5 mg/1OralPaddock Laboratories, Inc.2008-10-01Not applicableUs00574 0106 01 nlmimage10 e039701b
Bromocriptine mesylateTablet2.5 mg/1OralCarilion Materials Management2008-10-01Not applicableUs
Bromocriptine mesylateCapsule5 mg/1OralCadila Pharnmaceuticals2009-01-23Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralAvera Mc Kennan Hospital2016-03-08Not applicableUs
Bromocriptine MesylateTablet2.5 mg/1OralMylan Pharmaceuticals2013-06-06Not applicableUs
Bromocriptine mesylateTablet2.5 mg/1OralSandoz1998-01-13Not applicableUs
Bromocriptine MesylateCapsule5 mg/1OralAmerincan Health Packaging2010-01-132015-12-29Us
International/Other Brands
Apo-Bromocriptine (Apotex) / Bagren (Serono (Brazil)) / Ergoset / Parlodel Snaptabs (Novartis) / Pravidel (Meda (Germany, Sweden), Novartis (Canada, discontinued))
Categories
UNII
3A64E3G5ZO
CAS number
25614-03-3
Weight
Average: 654.595
Monoisotopic: 653.221282062
Chemical Formula
C32H40BrN5O5
InChI Key
OZVBMTJYIDMWIL-AYFBDAFISA-N
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1
IUPAC Name
(4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][[email protected]@]12CCCN1C(=O)[[email protected]](CC(C)C)N1C(=O)[[email protected]](NC(=O)[[email protected]]3CN(C)[[email protected]]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[[email protected]@]21O)C(C)C

Pharmacology

Indication

For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.

Structured Indications
Pharmacodynamics

Bromocriptine stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2-receptors. It also exhibits agonist activity (in order of decreasing binding affinity) on 5-hydroxytryptamine (5-HT)1D, dopamine D3, 5-HT1A, 5-HT2A, 5-HT1B, and 5-HT2C receptors, antagonist activity on α2A-adrenergic, α2C, α2B, and dopamine D1 receptors, partial agonist activity at receptor 5-HT2B, and inactivates dopamine D4 and 5-HT7 receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion making bromocriptine an effective agent for treating disorders associated with hypersecretion of prolactin. Pulmonary fibrosis may be associated bromocriptine’s agonist activity at 5-HT1B and 5-HT2B receptors.

Mechanism of action

The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders.

TargetActionsOrganism
AD(2) dopamine receptor
agonist
Human
AD(3) dopamine receptor
agonist
Human
U5-hydroxytryptamine receptor 1D
agonist
Human
UAlpha-2A adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 1A
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
UAlpha-2B adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 2B
agonist
Human
UD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
U5-hydroxytryptamine receptor 1B
agonist
Human
U5-hydroxytryptamine receptor 2C
agonist
Human
UD(1B) dopamine receptor
agonist
Human
UD(1A) dopamine receptor
agonist
Human
UAlpha-1A adrenergic receptor
agonist
Human
UAlpha-1B adrenergic receptor
agonist
Human
UAlpha-1D adrenergic receptor
agonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
Absorption

Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours.

Volume of distribution
Not Available
Protein binding

90-96% bound to serum albumin

Metabolism

Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion.

Route of elimination

Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney.

Half life

2-8 hours

Clearance
Not Available
Toxicity

Symptoms of overdosage include nausea, vomiting, and severe hypotension. The most common adverse effects include nausea, headache, vertigo, constipation, light-headedness, abdominal cramps, nasal congestion, diarrhea, and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Bromocriptine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Bromocriptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Bromocriptine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Bromocriptine.Experimental
AcebutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Bromocriptine can be increased when it is combined with Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Bromocriptine.Approved, Vet Approved
AdrafinilBromocriptine may increase the hypertensive activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bromocriptine.Approved
AlaproclateAlaproclate may increase the hypoglycemic activities of Bromocriptine.Experimental
AlbendazoleThe serum concentration of Bromocriptine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Bromocriptine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Bromocriptine can be increased when it is combined with Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bromocriptine.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Bromocriptine.Approved, Investigational
AlogliptinThe serum concentration of Bromocriptine can be increased when it is combined with Alogliptin.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Bromocriptine.Experimental
Alpha-1-proteinase inhibitorThe serum concentration of Bromocriptine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Bromocriptine can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Bromocriptine.Approved, Investigational
AmbroxolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ambroxol.Approved
AmibegronBromocriptine may increase the hypertensive activities of Amibegron.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Bromocriptine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amiloride.Approved
AmineptineAmineptine may decrease the antihypertensive activities of Bromocriptine.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Bromocriptine can be increased when it is combined with Aminohippuric acid.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Bromocriptine.Approved
AmiodaroneThe metabolism of Bromocriptine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe therapeutic efficacy of Amisulpride can be decreased when used in combination with Bromocriptine.Approved, Investigational
AmitrazBromocriptine may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
AmlodipineThe serum concentration of Bromocriptine can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bromocriptine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Bromocriptine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.Approved, Investigational
AmprenavirThe serum concentration of Bromocriptine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Bromocriptine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amyl Nitrite.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Anastrozole.Approved, Investigational
AnisodamineBromocriptine may increase the hypertensive activities of Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Antipyrine.Approved
Antithrombin III humanThe serum concentration of Bromocriptine can be increased when it is combined with Antithrombin III human.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Bromocriptine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Bromocriptine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineBromocriptine may increase the hypertensive activities of Arbutamine.Approved
ArformoterolBromocriptine may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Bromocriptine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bromocriptine.Approved, Investigational
ArotinololBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Bromocriptine.Approved, Investigational
AsenapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Asenapine.Approved
AstemizoleThe serum concentration of Bromocriptine can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Bromocriptine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtomoxetineThe metabolism of Bromocriptine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bromocriptine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azaperone.Vet Approved
AzelastineThe serum concentration of Bromocriptine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bromocriptine.Experimental
BarbitalBarbital may increase the hypotensive activities of Bromocriptine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Bromocriptine.Approved
BatimastatThe serum concentration of Bromocriptine can be increased when it is combined with Batimastat.Experimental
BefunololBromocriptine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Bromocriptine.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Bromocriptine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Bromocriptine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe serum concentration of Bromocriptine can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Bromocriptine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
BetaxololBromocriptine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BicalutamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bicalutamide.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifeprunox.Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bifonazole.Approved
BiperidenThe serum concentration of Bromocriptine can be increased when it is combined with Biperiden.Approved
BisoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BitolterolBromocriptine may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.Approved, Investigational
BlonanserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Blonanserin.Approved
BoceprevirThe metabolism of Bromocriptine can be decreased when combined with Boceprevir.Withdrawn
BopindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Bromocriptine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bromocriptine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bromocriptine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bromocriptine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the hypoglycemic activities of Bromocriptine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bromperidol.Investigational
BucindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolBromocriptine may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupivacaine.Approved, Investigational
BupranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Bromocriptine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Bromocriptine.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Butaperazine.Experimental
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Bromocriptine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Bromocriptine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Bromocriptine.Approved
CamostatThe serum concentration of Bromocriptine can be increased when it is combined with Camostat.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bromocriptine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Bromocriptine.Approved
Candesartan cilexetilThe serum concentration of Bromocriptine can be increased when it is combined with Candesartan.Approved
CandoxatrilThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Captopril.Approved
CarbamazepineThe metabolism of Bromocriptine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Bromocriptine.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Carbetocin.Approved
CarbomycinThe serum concentration of Bromocriptine can be increased when it is combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bromocriptine.Approved
CariprazineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Cariprazine.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Bromocriptine.Withdrawn
CarteololBromocriptine may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolBromocriptine may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Bromocriptine can be increased when it is combined with Caspofungin.Approved
CeliprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Bromocriptine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bromocriptine.Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Bromocriptine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorproethazine.Experimental
ChlorpromazineThe therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Bromocriptine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Bromocriptine.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Bromocriptine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Bromocriptine can be decreased when it is combined with Cholic Acid.Approved
ChymostatinThe serum concentration of Bromocriptine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Bromocriptine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilnidipine.Approved
CilostazolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilostazol.Approved
CimetidineThe serum concentration of Bromocriptine can be decreased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Withdrawn
CiprofloxacinThe serum concentration of Bromocriptine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CirazolineBromocriptine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bromocriptine.Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Bromocriptine.Approved
ClarithromycinThe metabolism of Bromocriptine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Bromocriptine can be decreased when combined with Clemastine.Approved
ClenbuterolBromocriptine may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clevidipine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bromocriptine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Bromocriptine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Bromocriptine.Approved, Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Bromocriptine.Approved, Nutraceutical
CloranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Bromocriptine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Bromocriptine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bromocriptine.Approved
CocaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bromocriptine.Approved
ColforsinThe serum concentration of Bromocriptine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Bromocriptine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Bromocriptine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Bromocriptine.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Bromocriptine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Bromocriptine.Approved
CyclophosphamideThe serum concentration of Bromocriptine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine.Approved
DabrafenibThe serum concentration of Bromocriptine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Bromocriptine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Bromocriptine can be increased when it is combined with Dactinomycin.Approved
DalfopristinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bromocriptine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bromocriptine.Investigational
DarexabanThe serum concentration of Bromocriptine can be increased when it is combined with Darexaban.Investigational
DarunavirThe metabolism of Bromocriptine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Bromocriptine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Bromocriptine can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Bromocriptine.Approved
DeferasiroxThe serum concentration of Bromocriptine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Bromocriptine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Bromocriptine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Bromocriptine can be decreased when combined with Delavirdine.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Bromocriptine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desflurane.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Bromocriptine.Approved
DesloratadineThe serum concentration of Bromocriptine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.Approved
DetomidineBromocriptine may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Bromocriptine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromocriptine.Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bromocriptine.Approved, Illicit, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Bromocriptine.Experimental
DiclofenacThe serum concentration of Bromocriptine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bromocriptine.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Bromocriptine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Bromocriptine.Approved
DigoxinThe serum concentration of Bromocriptine can be decreased when it is combined with Digoxin.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bromocriptine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Bromocriptine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Bromocriptine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bromocriptine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Bromocriptine.Illicit
DiltiazemThe metabolism of Bromocriptine can be decreased when combined with Diltiazem.Approved
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dimethyl sulfoxide.Approved, Vet Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dinutuximab.Approved
DipivefrinBromocriptine may increase the hypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Bromocriptine can be increased when it is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Dixyrazine.Experimental
DobutamineBromocriptine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Bromocriptine.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Bromocriptine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
DopexamineBromocriptine may increase the hypertensive activities of Dopexamine.Investigational
DosulepinDosulepin may decrease the antihypertensive activities of Bromocriptine.Approved
DoxazosinThe serum concentration of Bromocriptine can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Bromocriptine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bromocriptine.Approved, Investigational
DoxorubicinThe serum concentration of Bromocriptine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Bromocriptine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Bromocriptine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Bromocriptine can be decreased when combined with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Droperidol can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
DroxidopaBromocriptine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineBromocriptine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcabetThe serum concentration of Bromocriptine can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bromocriptine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Efonidipine.Approved
ElafinThe serum concentration of Bromocriptine can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Bromocriptine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Bromocriptine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Bromocriptine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Bromocriptine.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Bromocriptine.Approved
EnzalutamideThe serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.Approved
EpanololBromocriptine may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EphedrineBromocriptine may increase the hypertensive activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Bromocriptine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Bromocriptine.Approved, Investigational
EpinephrineBromocriptine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromocriptine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Bromocriptine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Bromocriptine.Approved, Investigational
ErythromycinThe serum concentration of Bromocriptine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Bromocriptine.Investigational
EsmololBromocriptine may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bromocriptine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Bromocriptine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Bromocriptine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Bromocriptine can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Bromocriptine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bromocriptine.Approved
EtilefrineBromocriptine may increase the hypertensive activities of Etilefrine.Withdrawn
EtoperidoneEtoperidone may increase the hypoglycemic activities of Bromocriptine.Approved
EtoposideThe serum concentration of Bromocriptine can be increased when it is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Bromocriptine can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bromocriptine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bromocriptine.Approved
FaldaprevirThe serum concentration of Bromocriptine can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe serum concentration of Bromocriptine can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fenoldopam.Approved
FenoterolBromocriptine may increase the hypertensive activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Bromocriptine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bromocriptine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Bromocriptine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Bromocriptine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fimasartan.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Bromocriptine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Bromocriptine can be decreased when combined with Fluconazole.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bromocriptine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Bromocriptine.Approved, Illicit
FlupentixolThe therapeutic efficacy of Flupentixol can be decreased when used in combination with Bromocriptine.Approved, Withdrawn
FluphenazineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Bromocriptine.Approved
FlurazepamThe serum concentration of Bromocriptine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bromocriptine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Bromocriptine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Bromocriptine.Approved, Investigational
FormoterolBromocriptine may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Bromocriptine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bromocriptine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Bromocriptine can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Bromocriptine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Bromocriptine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Bromocriptine can be increased when it is combined with Gabexate.Investigational
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Bromocriptine.Approved, Investigational
GeldanamycinThe serum concentration of Bromocriptine can be increased when it is combined with Geldanamycin.Experimental
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Bromocriptine.Approved
GemfibrozilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
GenisteinThe serum concentration of Bromocriptine can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Bromocriptine.Approved
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Bromocriptine.Investigational
GlyburideThe serum concentration of Bromocriptine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Bromocriptine can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Bromocriptine can be increased when it is combined with GM6001.Experimental
Gramicidin DThe serum concentration of Bromocriptine can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bromocriptine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Bromocriptine.Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Bromocriptine.Experimental
GuanabenzBromocriptine may increase the hypertensive activities of Guanabenz.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Guanfacine.Approved, Investigational
HaloperidolThe therapeutic efficacy of Haloperidol can be decreased when used in combination with Bromocriptine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypoglycemic activities of Bromocriptine.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Bromocriptine.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Bromocriptine.Approved
HexoprenalineBromocriptine may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineBromocriptine may increase the hypertensive activities of Higenamine.Investigational
HistamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Histamine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Bromocriptine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Bromocriptine.Approved
IdelalisibThe serum concentration of Bromocriptine can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Bromocriptine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ifosfamide.Approved
IloperidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Bromocriptine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Bromocriptine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Bromocriptine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Bromocriptine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indapamide.Approved
IndenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndinavirThe metabolism of Bromocriptine can be decreased when combined with Indinavir.Approved
indisulamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with indisulam.Investigational
IndomethacinThe serum concentration of Bromocriptine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indoramin.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bromocriptine.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Bromocriptine.Approved
IprindoleIprindole may decrease the antihypertensive activities of Bromocriptine.Experimental
IproclozideIproclozide may increase the hypoglycemic activities of Bromocriptine.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Bromocriptine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bromocriptine.Approved, Investigational
IsavuconazoniumThe metabolism of Bromocriptine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isocarboxazid.Approved
IsoetarineBromocriptine may increase the hypertensive activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoflurane.Approved, Vet Approved
IsoflurophateThe serum concentration of Bromocriptine can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoniazid.Approved
IsoprenalineBromocriptine may increase the hypertensive activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Bromocriptine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Bromocriptine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Bromocriptine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Bromocriptine.Approved, Vet Approved
IxazomibThe serum concentration of Bromocriptine can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Bromocriptine can be increased when it is combined with Josamycin.Approved
KetamineThe serum concentration of Bromocriptine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bromocriptine.Approved
KetoconazoleThe metabolism of Bromocriptine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Bromocriptine can be increased when it is combined with Kitasamycin.Experimental
LabetalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bromocriptine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bromocriptine.Approved, Investigational
LandiololBromocriptine may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LanreotideThe serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Bromocriptine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bromocriptine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bromocriptine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Bromocriptine.Approved
LepirudinThe serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Bromocriptine can be increased when it is combined with Letaxaban.Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bromocriptine.Approved, Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Bromocriptine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levobupivacaine.Approved
LevodopaBromocriptine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Bromocriptine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levomilnacipran.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Bromocriptine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Bromocriptine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Bromocriptine.Approved, Investigational
LiothyronineThe serum concentration of Bromocriptine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Bromocriptine can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lisinopril.Approved, Investigational
LisurideBromocriptine may increase the vasoconstricting activities of Lisuride.Approved
LithiumThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lithium.Approved
LofepramineLofepramine may decrease the antihypertensive activities of Bromocriptine.Experimental
LofexidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Bromocriptine can be increased when it is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lomustine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Bromocriptine.Approved
LopinavirThe metabolism of Bromocriptine can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Bromocriptine can be increased when it is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Bromocriptine.Approved
LosartanThe serum concentration of Bromocriptine can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Bromocriptine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe therapeutic efficacy of Loxapine can be decreased when used in combination with Bromocriptine.Approved
LuliconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Bromocriptine can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lumateperone.Investigational
LurasidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Bromocriptine.Illicit, Withdrawn
ManidipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Bromocriptine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
MebendazoleThe serum concentration of Bromocriptine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mecamylamine.Approved
MedetomidineBromocriptine may increase the hypertensive activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Bromocriptine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Bromocriptine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelagatranThe serum concentration of Bromocriptine can be increased when it is combined with Melagatran.Experimental
MelperoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Melperone.Approved
MephentermineBromocriptine may increase the hypertensive activities of Mephentermine.Approved
MepindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MeprobamateThe serum concentration of Bromocriptine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mequitazine.Approved
MesalazineMesalazine may increase the hypoglycemic activities of Bromocriptine.Approved
MesoridazineThe therapeutic efficacy of Mesoridazine can be decreased when used in combination with Bromocriptine.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Bromocriptine.Experimental
MetaraminolBromocriptine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Bromocriptine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Bromocriptine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methimazole.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bromocriptine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bromocriptine.Approved
MethotrimeprazineThe therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Bromocriptine.Approved
MethoxamineBromocriptine may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineBromocriptine may increase the hypertensive activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Bromocriptine.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Bromocriptine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bromocriptine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Bromocriptine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Bromocriptine.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Bromocriptine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metolazone.Approved
MetoprololBromocriptine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metyrapone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Bromocriptine.Experimental
MianserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mianserin.Approved
MibefradilThe serum concentration of Bromocriptine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Bromocriptine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineBromocriptine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Bromocriptine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Bromocriptine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Minoxidil.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Bromocriptine.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Bromocriptine.Approved
MitomycinThe serum concentration of Bromocriptine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Bromocriptine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bromocriptine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moexipril.Approved
MolindoneThe therapeutic efficacy of Molindone can be decreased when used in combination with Bromocriptine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moperone.Experimental
MorphineThe serum concentration of Morphine can be increased when it is combined with Bromocriptine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mosapramine.Experimental
MoxonidineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bromocriptine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Bromocriptine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nabilone.Approved, Investigational
NadololBromocriptine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafamostatThe serum concentration of Bromocriptine can be increased when it is combined with Nafamostat.Approved, Investigational
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Bromocriptine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bromocriptine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
NaltrexoneThe serum concentration of Bromocriptine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NandroloneNandrolone may increase the hypoglycemic activities of Bromocriptine.Experimental
NaphazolineBromocriptine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Bromocriptine.Approved, Investigational
NaringeninThe serum concentration of Bromocriptine can be increased when it is combined with Naringenin.Experimental
NebivololThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Bromocriptine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Bromocriptine can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
NeostigmineThe serum concentration of Bromocriptine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Bromocriptine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Bromocriptine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Bromocriptine.Withdrawn
NicardipineThe serum concentration of Bromocriptine can be increased when it is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Bromocriptine.Approved
NicorandilNicorandil may increase the hypotensive activities of Bromocriptine.Approved
NicotinamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nicotinamide.Approved
NifedipineThe serum concentration of Bromocriptine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Bromocriptine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bromocriptine.Approved
NisoldipineThe serum concentration of Bromocriptine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Bromocriptine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Bromocriptine.Investigational
NitroglycerinBromocriptine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitroprusside.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Bromocriptine.Approved
NorepinephrineBromocriptine may increase the hypertensive activities of Norepinephrine.Approved
NorethisteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Norethisterone.Approved
NorfenefrineBromocriptine may increase the hypertensive activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
NoscapineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Noscapine.Investigational
NylidrinBromocriptine may increase the hypertensive activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Bromocriptine.Withdrawn
OctopamineBromocriptine may increase the hypertensive activities of Octopamine.Experimental
OctreotideThe serum concentration of Bromocriptine can be increased when it is combined with Octreotide.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Bromocriptine.Investigational
OlanzapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Bromocriptine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Bromocriptine can be increased when it is combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Olmesartan.Approved, Investigational
OlodaterolBromocriptine may increase the hypertensive activities of Olodaterol.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Bromocriptine.Approved
OmapatrilatThe serum concentration of Bromocriptine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bromocriptine.Approved
OmeprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Bromocriptine.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Bromocriptine.Investigational
OrciprenalineBromocriptine may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Bromocriptine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Bromocriptine can be increased when it is combined with Otamixaban.Investigational
OxandroloneOxandrolone may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Bromocriptine.Experimental
OxprenololBromocriptine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxybutynin.Approved, Investigational
OxyfedrineBromocriptine may increase the hypertensive activities of Oxyfedrine.Experimental
OxymetazolineBromocriptine may increase the hypertensive activities of Oxymetazoline.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Bromocriptine.Approved, Illicit
OxypertineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Oxypertine.Experimental
P-NitrophenolThe serum concentration of Bromocriptine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Bromocriptine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Paliperidone.Approved
Palmitic AcidThe serum concentration of Bromocriptine can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Bromocriptine.Approved, Investigational
PantoprazoleThe serum concentration of Bromocriptine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Papaverine.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Paramethasone.Approved
PargylinePargyline may increase the hypoglycemic activities of Bromocriptine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromocriptine.Approved, Investigational
PasireotideThe serum concentration of Bromocriptine can be increased when it is combined with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Bromocriptine.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Bromocriptine.Approved
PenbutololBromocriptine may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Bromocriptine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perazine.Investigational
PergolideBromocriptine may increase the vasoconstricting activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Perindopril.Approved
PerospironeThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perospirone.Approved
PerphenazineThe therapeutic efficacy of Perphenazine can be decreased when used in combination with Bromocriptine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Bromocriptine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Bromocriptine.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
PhenobarbitalThe metabolism of Bromocriptine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Phentolamine.Approved
PhenylephrineBromocriptine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineBromocriptine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Bromocriptine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Bromocriptine can be increased when it is combined with Phosphoramidon.Experimental
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Bromocriptine.Approved
PiclozotanBromocriptine may increase the vasoconstricting activities of Piclozotan.Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pilocarpine.Approved
PimavanserinThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pimavanserin.Investigational
PimozideThe therapeutic efficacy of Pimozide can be decreased when used in combination with Bromocriptine.Approved
PindololBromocriptine may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.Approved
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Bromocriptine.Experimental
PipotiazineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipotiazine.Approved
PirbuterolBromocriptine may increase the hypertensive activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Bromocriptine.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Bromocriptine.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bromocriptine.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
Platelet Activating FactorThe serum concentration of Bromocriptine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bromocriptine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Bromocriptine.Approved
PosaconazoleThe metabolism of Bromocriptine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololBromocriptine may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.Approved
PrazosinThe serum concentration of Bromocriptine can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bromocriptine.Approved, Vet Approved
PrenalterolBromocriptine may increase the hypertensive activities of Prenalterol.Experimental
PrimaquineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Primaquine.Approved
PrimidoneThe metabolism of Bromocriptine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Bromocriptine can be increased when it is combined with Prinomastat.Investigational
ProbenecidThe serum concentration of Bromocriptine can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Bromocriptine.Approved
ProcaterolBromocriptine may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
ProgesteroneThe serum concentration of Bromocriptine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe therapeutic efficacy of Promazine can be decreased when used in combination with Bromocriptine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Bromocriptine.Approved
PropafenoneThe serum concentration of Bromocriptine can be increased when it is combined with Propafenone.Approved
PropericiazineThe therapeutic efficacy of Propericiazine can be decreased when used in combination with Bromocriptine.Approved
PropofolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololBromocriptine may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Bromocriptine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bromocriptine.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Bromocriptine.Investigational
PRX-00023Bromocriptine may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineBromocriptine may increase the hypertensive activities of Pseudoephedrine.Approved
QuercetinThe serum concentration of Bromocriptine can be increased when it is combined with Quercetin.Experimental
QuetiapineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quetiapine.Approved
QuinacrineThe serum concentration of Bromocriptine can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Bromocriptine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Bromocriptine can be increased when it is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Bromocriptine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineBromocriptine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Raclopride.Investigational
RactopamineBromocriptine may increase the hypertensive activities of Ractopamine.Vet Approved
RaloxifeneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Raloxifene.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ramipril.Approved
RanitidineThe serum concentration of Bromocriptine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bromocriptine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Bromocriptine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Bromocriptine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remifentanil.Approved
RemikirenThe serum concentration of Bromocriptine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Repaglinide.Approved, Investigational
ReproterolBromocriptine may increase the hypertensive activities of Reproterol.Investigational
ReserpineThe serum concentration of Bromocriptine can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Resveratrol.Experimental, Investigational
RifabutinThe metabolism of Bromocriptine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Bromocriptine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Bromocriptine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bromocriptine.Approved, Investigational
RilmenidineBromocriptine may increase the hypertensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Bromocriptine can be increased when it is combined with Rilpivirine.Approved
RimiterolBromocriptine may increase the hypertensive activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Riociguat.Approved
RisperidoneBromocriptine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ritanserin.Investigational
RitobegronBromocriptine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineBromocriptine may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe metabolism of Bromocriptine can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Bromocriptine.Approved
RolapitantThe serum concentration of Bromocriptine can be increased when it is combined with Rolapitant.Approved
RolitetracyclineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rolitetracycline.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Bromocriptine.Approved, Investigational
RomifidineBromocriptine may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ropivacaine.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Bromocriptine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Bromocriptine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rotigotine.Approved
RoxithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Roxithromycin.Approved, Withdrawn
RP5063The therapeutic efficacy of Bromocriptine can be decreased when used in combination with RP5063.Investigational
RufloxacinRufloxacin may increase the hypoglycemic activities of Bromocriptine.Experimental
RutinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Rutin.Experimental
S-3304The serum concentration of Bromocriptine can be increased when it is combined with S-3304.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Bromocriptine.Withdrawn
SalbutamolBromocriptine may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Bromocriptine.Approved, Vet Approved
SalmeterolBromocriptine may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe metabolism of Bromocriptine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sarilumab.Approved
SaxagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe serum concentration of Bromocriptine can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Bromocriptine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Bromocriptine.Approved
SertindoleThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Bromocriptine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Bromocriptine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.Approved
SiltuximabThe serum concentration of Bromocriptine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Bromocriptine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Bromocriptine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Bromocriptine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Bromocriptine.Experimental
SitaxentanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Bromocriptine can be increased when it is combined with Sivelestat.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bromocriptine.Approved
SolabegronBromocriptine may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Bromocriptine can be increased when it is combined with Solithromycin.Investigational
SomatostatinThe serum concentration of Bromocriptine can be increased when it is combined with Somatostatin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Bromocriptine.Approved, Investigational
SotalolBromocriptine may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Bromocriptine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bromocriptine.Experimental
SpiraprilThe serum concentration of Bromocriptine can be increased when it is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Bromocriptine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Bromocriptine can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Bromocriptine.Approved, Vet Approved
StaurosporineThe serum concentration of Bromocriptine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Bromocriptine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Bromocriptine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.Approved, Investigational
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulfanilamide.Approved
SulfinpyrazoneThe serum concentration of Bromocriptine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Bromocriptine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Bromocriptine.Approved, Investigational
SunitinibThe serum concentration of Bromocriptine can be increased when it is combined with Sunitinib.Approved, Investigational
SynephrineBromocriptine may increase the hypertensive activities of Synephrine.Experimental
TacrineThe serum concentration of Bromocriptine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Bromocriptine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tadalafil.Approved, Investigational
TalinololBromocriptine may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamoxifenThe serum concentration of Bromocriptine can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Bromocriptine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bromocriptine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Bromocriptine.Approved
TelaprevirThe metabolism of Bromocriptine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Bromocriptine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Bromocriptine can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Bromocriptine.Withdrawn
TemocaprilThe serum concentration of Bromocriptine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Bromocriptine.Approved
TeniposideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Teniposide.Approved
TerazosinThe serum concentration of Bromocriptine can be increased when it is combined with Terazosin.Approved
TerbutalineBromocriptine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe serum concentration of Bromocriptine can be increased when it is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Bromocriptine.Experimental
TertatololBromocriptine may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TesmilifeneThe serum concentration of Bromocriptine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Bromocriptine can be increased when it is combined with Testosterone.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Bromocriptine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Thiopropazate.Experimental
ThioproperazineThe therapeutic efficacy of Thioproperazine can be decreased when used in combination with Bromocriptine.Approved
ThioridazineThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Bromocriptine.Withdrawn
ThiorphanThe serum concentration of Bromocriptine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe therapeutic efficacy of Thiothixene can be decreased when used in combination with Bromocriptine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Bromocriptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Bromocriptine.Approved
TiclopidineThe metabolism of Bromocriptine can be decreased when combined with Ticlopidine.Approved
TimololBromocriptine may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tioconazole.Approved
TipranavirThe serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Bromocriptine.Approved
TocilizumabThe serum concentration of Bromocriptine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tofisopam.Approved
TolazolineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypoglycemic activities of Bromocriptine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bromocriptine.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Topiroxostat.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bromocriptine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Torasemide.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Bromocriptine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromocriptine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Bromocriptine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromocriptine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bromocriptine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromocriptine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolBromocriptine may increase the hypertensive activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Triamterene.Approved
TrifluoperazineThe therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Bromocriptine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trifluperidol.Experimental
TriflupromazineThe serum concentration of Bromocriptine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Bromocriptine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Bromocriptine.Approved
TroglitazoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Troglitazone.Withdrawn
TroleandomycinThe serum concentration of Bromocriptine can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Bromocriptine.Approved, Investigational
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Withdrawn
TulobuterolBromocriptine may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Bromocriptine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Bromocriptine can be increased when it is combined with Ubenimex.Experimental
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Bromocriptine.Experimental
UlinastatinThe serum concentration of Bromocriptine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Bromocriptine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bromocriptine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Valsartan.Approved, Investigational
VapreotideThe serum concentration of Bromocriptine can be increased when it is combined with Vapreotide.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Bromocriptine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Bromocriptine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Bromocriptine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Bromocriptine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Veralipride.Experimental
VerapamilThe metabolism of Bromocriptine can be decreased when combined with Verapamil.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Bromocriptine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Bromocriptine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Bromocriptine.Approved, Investigational
VincristineThe serum concentration of Bromocriptine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Bromocriptine can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bromocriptine.Approved
VoriconazoleThe metabolism of Bromocriptine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Bromocriptine.Approved
XamoterolBromocriptine may increase the hypertensive activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Bromocriptine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineBromocriptine may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Bromocriptine may increase the hypertensive activities of YM-178.Investigational
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Bromocriptine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bromocriptine.Approved
ZimelidineThe serum concentration of Bromocriptine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Ziprasidone.Approved
ZofenoprilThe serum concentration of Bromocriptine can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Bromocriptine.Approved, Investigational
ZotepineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Zotepine.Approved
ZucapsaicinThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Zucapsaicin.Approved
ZuclopenthixolThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Luigi Moro, Achille Fiori, Alberto Natali, "Processes for the preparation of pharmaceutical compositions containing bromocriptine having high stability and related products." U.S. Patent US5066495, issued May, 1988.

US5066495
General References
  1. Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002 Oct;16(10):2393-404. [PubMed:12351703]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  4. Malgaroli A, Vallar L, Elahi FR, Pozzan T, Spada A, Meldolesi J: Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action. J Biol Chem. 1987 Oct 15;262(29):13920-7. [PubMed:2443499]
  5. Nishina Y, Takano K, Yasufuku-Takano J, Teramoto A, Fujita T: Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. Endocr J. 2005 Dec;52(6):775-9. [PubMed:16410672]
  6. Vallar L, Meldolesi J: Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci. 1989 Feb;10(2):74-7. [PubMed:2655242]
  7. Vallar L, Vicentini LM, Meldolesi J: Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells. J Biol Chem. 1988 Jul 25;263(21):10127-34. [PubMed:2839476]
External Links
Human Metabolome Database
HMDB15331
KEGG Drug
D03165
KEGG Compound
C06856
PubChem Compound
31101
PubChem Substance
46505504
ChemSpider
28858
BindingDB
81993
ChEBI
3181
ChEMBL
CHEMBL493
Therapeutic Targets Database
DAP001462
PharmGKB
PA448671
HET
08Y
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromocriptine
ATC Codes
G02CB01 — BromocriptineN04BC01 — Bromocriptine
AHFS Codes
  • 28:36.20.04 — Ergot-derivative Dopamine Receptor Agonists
PDB Entries
3ua1 / 5vcg
FDA label
Download (105 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentEndometriosis of Uterus1
1CompletedTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentPeripartum Cardiomyopathy1
2Not Yet RecruitingTreatmentOvarian Hyperstimulation Syndrome1
2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2SuspendedTreatmentMental Retardation / Stereotyped Behavior1
3CompletedTreatmentIdiopathic Parkinson's Disease1
3CompletedTreatmentParkinson's Disease (PD)2
3CompletedTreatmentType 2 Diabetes Mellitus1
3Not Yet RecruitingTreatmentPeripartum Cardiomyopathy1
3TerminatedTreatmentType 2 Diabetes Mellitus1
3Unknown StatusNot AvailableInsulin Resistance / Polycystic Ovarian Syndrome1
4CompletedTreatmentParkinson's Disease (PD)2
4CompletedTreatmentType 2 Diabetes Mellitus1
4RecruitingTreatmentDiabetic Autonomic Neuropathy1
4RecruitingTreatmentType 2 Diabetes Mellitus1
4Unknown StatusTreatmentHyperaldosteronism / Hypertensive1
Not AvailableActive Not RecruitingBasic ScienceAddictions1
Not AvailableCompletedNot AvailableBMI >30 kg/m21
Not AvailableCompletedNot AvailableInsulin Sensitivity1
Not AvailableCompletedTreatmentCirrhosis Related Parkinsonism / Hepatic/Cirrhosis Related Parkinsonism1
Not AvailableTerminatedTreatmentGraves Ophthalmopathy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral5 mg
TabletOral2.5 mg
CapsuleOral5 mg/1
TabletOral2.5 mg/1
TabletOral.8 mg/1
CapsuleOral5.0 mg
Capsule, gelatin coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Bromocriptine mesylate powd384.03USD g
Parlodel 5 mg capsule9.25USD capsule
Parlodel 2.5 mg tablet5.64USD tablet
Bromocriptine Mesylate 5 mg capsule5.21USD capsule
Bromocriptine Mesylate 2.5 mg tablet2.28USD tablet
Bromocriptine 2.5 mg tablet2.18USD tablet
Apo-Bromocriptine 5 mg Capsule1.02USD capsule
Pms-Bromocriptine 5 mg Capsule1.02USD capsule
Apo-Bromocriptine 2.5 mg Tablet0.57USD tablet
Pms-Bromocriptine 2.5 mg Tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5716957No1995-02-102015-02-10Us
US5468755No1992-11-212012-11-21Us
US8613947No2012-04-302032-04-30Us
US7888310No2003-07-252023-07-25Us
US8431155No2012-04-302032-04-30Us
US8137993No2003-07-252023-07-25Us
US8137992No2003-07-252023-07-25Us
US8137994No2003-07-252023-07-25Us
US8877708No2010-06-072030-06-07Us
US9192576No2012-04-302032-04-30Us
US9522117No2012-04-302032-04-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)215-218Fluckiger, E.,Troxler, F. and Hofmann, A,; US. Patent 3,752,814; August 14, 1973; assigned to Sandoz Ltd., Switzerland. Fluckiger, E., Troxler, F. and Hofmann, A.; U.S. Patent 3,752,888; August 14, 1973; assigned to Sandoz Ltd., Switzerland.
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0858 mg/mLALOGPS
logP3.2ALOGPS
logP3.89ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)9.68ChemAxon
pKa (Strongest Basic)6.71ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity165.51 m3·mol-1ChemAxon
Polarizability66.44 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.915
Blood Brain Barrier-0.9845
Caco-2 permeable-0.6618
P-glycoprotein substrateSubstrate0.8881
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7454
CYP450 1A2 substrateNon-inhibitor0.9031
CYP450 2C9 inhibitorInhibitor0.8326
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5149
Ames testNon AMES toxic0.7879
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.9973
Rat acute toxicity2.7499 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9313
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergamides
Alternative Parents
Indoloquinolines / Benzoquinolines / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Isoindoles and derivatives / Aralkylamines / N-alkylpiperazines / Aryl bromides / Benzenoids
show 18 more
Substituents
Lysergic acid amide / Indoloquinoline / Benzoquinoline / N-acyl-alpha amino acid or derivatives / Pyrroloquinoline / Alpha-amino acid or derivatives / Quinoline / 3-alkylindole / Indole / Indole or derivatives
show 42 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
indole alkaloid (CHEBI:3181)

Targets

Details
1. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Cavallotti C, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):412-8. [PubMed:12010185]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  4. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
  5. Lahlou S: Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats. Fundam Clin Pharmacol. 1999;13(6):624-34. [PubMed:10626749]
  6. Lahlou S, Araujo Lima PF, Interaminense LF, Duarte GP: Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats. Pharmacol Toxicol. 2003 Apr;92(4):189-94. [PubMed:12753422]
  7. Lahlou S, Lima GC, Leao-Filho CS, Duarte GP: Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats. Can J Physiol Pharmacol. 2000 Mar;78(3):260-5. [PubMed:10721819]
  8. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L: Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001 Apr;14(3):329-36. [PubMed:11444429]
Details
2. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B: The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol. 2010 Jun 15;79(12):1827-36. doi: 10.1016/j.bcp.2010.01.029. Epub 2010 Feb 4. [PubMed:20138024]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I: Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30. [PubMed:18703043]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Details
13. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Details
14. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. [PubMed:10641988]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Knight JA, Smith C, Toohey N, Klein MT, Teitler M: Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists. Mol Pharmacol. 2009 Feb;75(2):374-80. doi: 10.1124/mol.108.052084. Epub 2008 Nov 7. [PubMed:18996971]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Fernando H, Halpert JR, Davydov DR: Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry. 2006 Apr 4;45(13):4199-209. [PubMed:16566594]
  2. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. [PubMed:18691132]
  3. Nath A, Grinkova YV, Sligar SG, Atkins WM: Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem. 2007 Sep 28;282(39):28309-20. Epub 2007 Jun 15. [PubMed:17573349]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  4. Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, Hui Bon Hoa GH: Thermodynamic studies of substrate binding and spin transitions in human cytochrome P-450 3A4 expressed in yeast microsomes. Biochem J. 1996 Nov 1;319 ( Pt 3):675-81. [PubMed:8920966]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:28